News

Lundbeckfonden Ventures News

  DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, presented six clinical and preclinical presentations on Epicutaneaous Immunotherapy (EPIT®) at the European Academy of Allergy & Clinical Immunology & World Allergy Organization & World Allergy & Asthma Congress (EAACI-WAO) in Milan, Italy. DBV’s Viaskin technology...
   LCP-Tacro, once-daily, demonstrated non-inferiority to Prograf®, twice-daily, based on the composite endpoint of treatment failure at one year (LCP-TacroTM 18.3%, Prograf® 19.6%) Treatment failure rates through the first three months after transplant were 10.4% for LCP-TacroTM and 14.2% for Prograf® Similar incidence of adverse events and impact on laboratory results reported for LCP-TacroTM and...
  ColoAd1 study to compare direct intra-tumoral with intravenous injection in patients with non-metastatic colorectal cancer PsiOxus Therapeutics, Ltd. (PsiOxus), a development stage biotechnology company, will initiate a clinical trial of ColoAd1, a systemically available oncolytic vaccine, to compare the effectiveness of direct intra-tumoral injection with intravenous injection in patients with non-metastatic colorectal cancer. The...
  o Two-thirds of 5-11 years old children reached efficacy endpoint after 18-month treatmento ARACHILD provides a very good baseline for DBV’s ongoing phase IIb (‘VIPES’) study DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today the 6-, 12- and 18-month efficacy data of...
  River Vision Development Corp. (River Vision) today announced that RV001, the Company's human monoclonal antibody teprotumumab, has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of active phase Graves Orbitopathy (GO), also known as Thyroid Eye Disease.  GO is a condition afflicting a proportion of Graves'...
  DBV Technologies (Euronext: DBV – ISIN: FR0010417345), creator of Viaskin®, a new standard in the treatment of allergy, announced today the appointment of Véronique Foutel as Chief Strategic Marketing Officer. In this position and in full partnership with the other members of the DBV leadership team, Véronique will be accountable for developing a sustainable...
  Celladon Corporation, a biopharmaceutical company focused on the discovery and development of innovative treatments for cardiovascular diseases announced today it had been selected as a winner of Red Herring's Top 100 North America award, a prestigious list honoring the year’s most promising private technology ventures from the North American business region We are proud...
  Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that the European Medicines Agency (EMA) accepted for review the company’s Marketing Authorization Application (MAA) to market LCP-Tacro for the prevention of organ rejection in kidney transplant patients in the European Union. Veloxis expects the decision from the European Union in 2014.  For Investor and media contact:John...
  Data from the STRATO Study Presented at the 13th American Transplant Congress Veloxis Pharmaceuticals A/S (OMX: VELO) today announced that data from the STRATO study demonstrates the potential for LCP-TacroT to improve tacrolimus-induced tremors in stable kidney transplant patients. The study, Switching STudy of Kidney TRansplant PAtients with Tremor to LCP-TacrOT (STRATO) clinical trial,...
1 43 44 45 46 47 54

Lundbeckfonden Ventures

News

BONESUPPORT HOLDING AB (publ) – Invitation to conference call in connection of the Full Year Report 2018
20. February 2019
Atox Bio Announces Appointment of Robert Greif as Chief Commercial Officer
18. February 2019
BONESUPPORT – Publication of pre-clinical study highlighting unique bone remodeling qualities of CERAMENT® in large bone defects
8. February 2019